Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials

Published:2023-05-02 Issue:3 Volume:41 Page:453-462
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Li Xiaoli,Liu Yuyan,Zhu Minhui,He Cuixia,Xu Yuanyuan,Ding Jiaxiang,Wang Ying,Shan Rongfang,Liu Bingyan,Ding Yuzhou,Xie Jing,Zhou Huan,Wang Zhiqiang,Liu Yuanyuan

Funder

512 Talent Fund” of Bengbu Medical College

Research and development project commissioned by Nanjing Sanhome Pharmaceutical Co., Ltd

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-023-01356-5.pdf

Reference18 articles.

1. Spiro SG (2005) One hundred years of lung cancer. Am J Respir Crit Care Med 172(5):523–529. https://doi.org/10.1164/rccm.200504-531OE

2. Nasim F, Sabath BF (2019) Lung Cancer. Med Clin North Am 103(3):463–473. https://doi.org/10.1016/j.mcna.2018.12.006

3. Zappa C (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5(3):288–300. https://doi.org/10.21037/tlcr.2016.06.07

4. Molina JR, Yang P, Cassivi SD, Schild SE (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584

5. Herbst RS, Morgensztern D (2018) The biology and management of non-small cell lung cancer. Nature 553(7689):446–454. https://doi.org/10.1038/nature25183

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP